SEARCH
How Far in Advance Should Executives Schedule 1-to-1 Meetings for BIO?
For executives in biotech and pharma, the BIO International Convention represents a pivotal opportunity to connect with partners, investors, and decision-makers who can shape their company’s trajectory. But with thousands of companies vying for attention—including giants like Bristol Myers Squibb, Pfizer, and Amgen—timing is everything when it comes to booking those coveted one-to-one meetings.
So, how far in advance should executives be scheduling these meetings? And how do partnering platforms such as the BIO Partnering platform and the LSX partnering platform factor into strategic conference planning? This post will break down the best practices, focusing on objective-first conference selection, navigating capital markets and investor access, and engaging health system adoption and formulary stakeholders.
Executive Conference Planning: Start With Your Objectives
Before diving into the logistics of scheduling meetings weeks—or even months—ahead, it’s crucial to nail down why executives are attending BIO in the first place. I always ask clients: What’s the meeting math? In other words, what are you hoping to accomplish, and how many targeted meetings are needed to hit those goals?
Common objectives include:
- Business Development: Connecting with potential partners or licensees.
- Capital Markets & Investor Access: Engaging with investors ahead of fundraises, like the oversubscribed $5 Million fundraise for PlaqueTec Limited.
- Health System & Formulary Engagement: Meeting with hospital decision-makers and payers to drive adoption.
Aligning your meeting goals with your time investment guides when and how to book. Rushing to schedule 1:1s at the last minute often leads to low-value sessions and missed opportunities.
Partnering Platforms: Your Secret Weapon for Booking Meetings Weeks Ahead
Online partnering platforms have revolutionized the mechanics of meeting scheduling at events like BIO. They transform a chaotic, walk-up meeting approach into a structured, strategic partnering journey.
BIO Partnering Platform: Pre-Schedule Weeks in Advance
The BIO Partnering platform allows executives to begin browsing company profiles, requesting meetings, and confirming times well before the conference kicks off. This advance scheduling isn’t just convenient—it’s essential.
Here’s why:
- High-demand meetings fill up quickly. For example, meetings with decision-makers from Bristol Myers Squibb or Amgen are often booked weeks ahead. Trying to secure times closer to BIO is a losing game of musical chairs.
- Enables thoughtful agenda design. Knowing your confirmed meetings lets you carve out focused time blocks for follow-ups or panels.
- Minimizes no-shows and scheduling conflicts. Confirmed slots reduce wasted time on both sides.
For executives, the golden rule is: Book meetings 4–6 weeks before the event. Many BIO Partnering invitations open around 6–8 weeks ahead, so jump on them immediately.
LSX Partnering Platform: Specialty Meeting Management
In addition to BIO’s platform, some teams leverage tools like the LSX partnering platform, known for its one-to-one meeting scheduling capabilities tailored to biotech’s investor and corporate development communities.
While LSX may focus more on follow-up and post-conference meetings, it complements BIO partnering by helping extend connectivity beyond the event floor.
Capital Markets & Investor Access: Timing Your Fundraise Conversations
Capital markets represent an especially time-sensitive use case for 1:1s. Consider the oversubscribed $5 Million fundraise by PlaqueTec Limited—an example recently noted in editor picks for demonstrating how precise timing can make or break investor engagement.
For executives gearing up for fundraising discussions at BIO:
Trying to “network” your way into investor meetings onsite rarely yields results, especially when competing with heavy hitters like Pfizer’s corporate VC or BD teams.
Health System Adoption & Formulary Decision-Makers: Early Engagement Pays Off
For companies targeting health system adoption, including payers and formulary managers, BIO can be a fertile environment for meetings—but only if well health system formulary decision makers planned.
The shift to value-based care means forming relationships months ahead is crucial, especially to:
- Understand payer coverage policies.
- Discuss real-world evidence generation.
- Introduce pipeline assets to formulary decision-makers.
Industry leaders at Bristol Myers Squibb and Amgen already capitalize on these early meetings to refine messaging and build trust. Using the BIO Partnering platform, companies should aim to:
This approach prevents the common mistake of leaving these critical conversations until late in the week, causing rushed interactions and suboptimal outcomes.
Putting It All Together: Timeline and Tips for Effective BIO Partnering Prep
Final Thoughts: Don’t Leave Your Executive Agenda to Chance
In my experience staffing meeting weeks for biotech and pharma teams, the difference between a productive BIO and a missed opportunity often boils down to lead time and preparation. Executives must adopt an objective-first approach to conference attendance and leverage partnering platforms like BIO’s own system to book meetings weeks ahead. This is non-negotiable when engaging with powerful companies like Bristol Myers Squibb, Pfizer, and Amgen, or when advancing investor conversations tied to critical capital raises.
Beyond just “great networking,” these platforms provide the structure to build a purposeful, measurable meeting agenda that maximizes ROI. So next time you prepare for BIO, start early, be intentional, and secure those meetings well before the crowd sets in.
